quantisnow
FeedTopReportsPricing
⌘K
Live feed
09:20:00·52d
PRRelease
Scinai Immunotherapeutics Ltd. logo

Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept

SCNI· Scinai Immunotherapeutics Ltd.
Health Care
Original source

Companies

  • SCNI
    Scinai Immunotherapeutics Ltd.
    Health Care

Related

  • PR17d
    Scinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 Priorities
  • PR22d
    Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration
  • SEC22d
    SEC Form 20-F filed by Scinai Immunotherapeutics Ltd.
  • INSIDER28d
    SEC Form 3 filed by new insider Mark Elad
  • SEC31d
    SEC Form 6-K filed by Scinai Immunotherapeutics Ltd.
  • SEC35d
    SEC Form 6-K filed by Scinai Immunotherapeutics Ltd.
  • PR35d
    Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026
  • INSIDER36d
    SEC Form 3 filed by Scinai Immunotherapeutics Ltd.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022